Department of Otorhinolaryngology Head and Neck Surgery, 34708Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.
Department of Anesthesiology, 34708Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China.
Int J Immunopathol Pharmacol. 2022 Jan-Dec;36:3946320221107239. doi: 10.1177/03946320221107239.
Osteoporosis (OP) is determined as a chronic systemic bone disorder to increase the susceptibility to fracture. Ginsenosides have been found the anti-osteoporotic activity of in vivo and in vitro. However, its mechanism remains unknown. The potential mechanism of ginsenosides in anti-osteoporotic activity was identified by using network phamacology analysis. The active compounds of ginsenosides and their targets associated to OP were retrieved from Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform, Drug Bank, Pharmmapper, and Cytoscape. The Gene ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis target genes were performed in String, Phenopedia, DisGeNET database, and Metascape software. The protein to protein interaction were created by String database and Cytoscape software. The molecular docking was used to investigate the interactions between active coumpounds and potential targets by utilizing SwissDock tool, UCSF Chimera, and Pymol software. A total of eight important active ingredients and 17 potential targets related to OP treatment were subjected to analyze. GO analysis showed the anti-osteoporosis targets of ginsenoside mainly play a role in the response to steroid hormone. KEGG enrichment analysis indicated that ginsenoside treats OP by osteoblast differentiation signal pathway. Lastly, the molecular docking outcomes indicated that ginsenoside rh2 had a good binding ability with four target proteins IL1B, TNF, IFNG, and NFKBIA. IL1B, TNF, IFNG, and NFKBIA are the most important targets and osteoblast differentiation is the most valuable signaling pathways in ginsenoside for the treatment of OP, which might be beneficial to elucidate the mechanism concerned to the action of ginsenoside and might supply a better understanding of its anti-OP effects.
骨质疏松症（OP）是一种慢性全身性骨骼疾病，会增加骨折的易感性。已发现人参皂苷具有体内和体外的抗骨质疏松活性。然而，其机制尚不清楚。通过网络药理学分析确定了人参皂苷在抗骨质疏松活性中的潜在机制。从中药系统药理学数据库和分析平台、药物银行、Pharmmapper 和 Cytoscape 中检索到人参皂苷的活性化合物及其与 OP 相关的靶点。在 String、Phenopedia、DisGeNET 数据库和 Metascape 软件中对基因本体论（GO）富集分析和京都基因与基因组百科全书（KEGG）途径分析靶基因进行分析。通过 String 数据库和 Cytoscape 软件创建蛋白质-蛋白质相互作用。利用 SwissDock 工具、UCSF Chimera 和 Pymol 软件研究活性化合物与潜在靶标的相互作用，进行分子对接。共分析了 8 种重要的与 OP 治疗相关的活性成分和 17 个潜在靶点。GO 分析表明，人参皂苷的抗骨质疏松作用靶点主要在甾体激素反应中发挥作用。KEGG 富集分析表明，人参皂苷通过成骨细胞分化信号通路治疗 OP。最后，分子对接结果表明，人参皂苷 rh2 与 4 种靶蛋白 IL1B、TNF、IFNG 和 NFKBIA 具有良好的结合能力。IL1B、TNF、IFNG 和 NFKBIA 是人参皂苷治疗 OP 最重要的靶标，成骨细胞分化是人参皂苷治疗 OP 最有价值的信号通路，这可能有助于阐明人参皂苷作用的相关机制，并更好地理解其抗 OP 作用。
